Emergent BioSolutions’ ACAM2000® Gains FDA Approval for Mpox Use
Emergent BioSolutions Inc. (NYSE: EBS) has announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ACAM2000®, a live vaccine for smallpox and mpox (Vaccinia). This approval enables the vaccine to be used for preventing mpox disease in individuals identified as being at high risk for infection. The decision is backed by existing human safety data and findings from a controlled animal study that demonstrated the vaccine's effectiveness against the mpox virus.
ACAM2000®: A Convenient Single-Dose Vaccine
ACAM2000® is given as a single-dose vaccine using a bifurcated needle technique. This involves dipping the needle into the vaccine solution and pricking the skin multiple times with the droplet on the upper arm.
Background of ACAM2000®
Initially approved by the FDA in 2007, ACAM2000® was designated for active immunization against smallpox in individuals at high risk for infection. Mpox, previously known as monkeypox, is an infectious disease endemic to certain areas, caused by the mpox virus, which belongs to the Orthopoxvirus genus in the Poxviridae family, closely related to the virus that led to the eradication of smallpox in 1980.
Significance of the Approval
“The FDA's approval of ACAM2000® for immunization against mpox in high-risk individuals strengthens our smallpox vaccine portfolio, which includes other products like VIGIV® and TEMBEXA®,” said Joe Papa, president and CEO of Emergent. “This expanded indication comes at a critical time as the global health community works to effectively respond to the recent increase in mpox cases.” Emergent BioSolutions is actively involved in global health discussions and readiness efforts to address the public health needs arising from mpox outbreaks.
Emergent's Support Amid Global Health Concerns
This FDA approval comes at a time when mpox has become a significant public health issue. Emergent has pledged to donate 50,000 doses of ACAM2000® to support public health initiatives in regions affected by mpox outbreaks, particularly in Central Africa. The rising number of mpox cases underscores the need to utilize effective vaccination strategies.
Understanding Mpox Variants and Associated Risks
Recent reports indicate that the clade I variant of mpox is associated with more severe clinical outcomes and a higher mortality rate, highlighting the need for timely intervention. Additionally, the newly identified clade Ib variant is known for its increased transmissibility, which has led to a rise in cases among vulnerable populations, especially children and families.
About ACAM2000®
ACAM2000® is recognized as the primary smallpox vaccine designated for emergencies related to bioterrorism, with supplies distributed to the U.S. Strategic National Stockpile. This vaccine is not only licensed in the United States but also in several other countries, including Canada, Australia, and Singapore.
Safety Profile and Precautions
While ACAM2000® is a vital tool for preventing smallpox and mpox infections in at-risk individuals, it does have contraindications. Specifically, individuals with severe immunodeficiency should avoid this vaccine due to the risks of progressive vaccinia. There are also precautions regarding potential side effects, such as myocarditis, pericarditis, and other significant health risks.
Emergent BioSolutions: A Commitment to Public Health
Emergent BioSolutions is dedicated to improving lives and safeguarding public health amidst complex health challenges. The company develops innovative solutions tailored to urgent public health threats, backed by a strong portfolio of vaccines and therapeutics. To learn more about their commitment and advancements in health security, you can explore their official channels and communication platforms.
Frequently Asked Questions
What is ACAM2000® used for?
ACAM2000® is indicated for preventing smallpox and mpox disease in individuals identified as high risk for infection.
What led to the FDA approval for the mpox indication?
The FDA's approval was based on human safety data and a controlled animal study demonstrating ACAM2000®'s effectiveness against exposure to the mpox virus.
Who benefits from the expanded indication of ACAM2000®?
The approval allows for vaccination of individuals deemed high-risk, which is crucial for managing mpox outbreaks, especially during global health emergencies.
How does ACAM2000® differ from earlier smallpox vaccines?
ACAM2000® employs a modern administration technique and is designed as a single-dose vaccine, unlike previous vaccines that required multiple doses.
Where can I find more information about the safety of ACAM2000®?
Additional details regarding the safety and efficacy of ACAM2000® can be found in its prescribing information and clinical resources provided by Emergent BioSolutions.
